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Surgery is the standard treatment for a primary gastrointestinal stromal tumor (GIST); however, surgical resection is often 
not curative, particularly for large GISTs. In the past decade, with imatinib mesylate (IM), management strategies for GISTs 
have evolved significantly, and now IM is the standard care for patients with locally advanced, recurrent or metastatic GISTs. 
Adjuvant therapy with imatinib was recently approved for use, and preoperative imatinib is an emerging treatment option 
for patients who require cytoreductive therapy. IM neoadjuvant therapy for primary GISTs has been reported, but there is 
no consensus on the dose of the drug, the duration of treatment and the optimal time of surgery. These are critical because 
drug resistance or tumor progression can develop with a prolonged treatment. This report describes two cases of large rec-
tal malignant GISTs, for which a abdominoperineal resection was initially anticipated. The two patients received IM pre-
operative treatment; we followed-up with CT or magnetic resonance imaging to access the response. After 9 months of treat-
ment, a multi-disciplinary consensus that maximal benefit from imatinib had been achieved was reached. We determined 
the best time for surgical intervention and successfully performed sphincter-preserving surgery before resistance to ima-
tinib or tumor progression occurred. We believe that a multidisciplinary team approach, considerating the optimal dura-
tion of therapy and the timing of surgery, is required to optimize treatment outcome.
Keywords: Gastrointestinal stromal tumors; Imatinib; Ultralow anterior resection; Coloanal anastomosis; Neoadjuvant treat-
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sis, ultimately leading to an aberrant growth, neoplasia [3]. GISTs 
span a wide clinical spectrum from benign to highly malignant 
and even metastatic [7], and harbor the potential risk of local and 
distant recurrence, making them difficult to cure [8, 9]. Imatinib 
mesylate (STI-571; Glivec/Gleevec, Norvatis Pharmaceuticals, Ba-
sel, Switzerland), a KIT and PDGFR-α inhibitor, is now standard 
care for patients with locally unresectable or metastatic GISTs and 
was recently approved for use in the adjuvant therapy setting in 
the United States and Europe [10, 11].
CASE REPORTS
Case 1
A 56-year-old man was referred to our hospital complaining of a 
6-month history of constipation and tenesmus. His past medical 
history was unremarkable. Standard laboratory tests of serum and 
urine showed no abnormalities. Carcinoembryonic antigen (CEA) 
and carbohydrate antigen 19-9 (CA19-9) were within normal lim-
its. A clinical examination did not detect any palpable abdominal 
mass. Digital investigation of the rectum revealed a mass of approx-
imately 8 cm in diameter on the left lateral rectal wall about 3.7 cm 
INTRODUCTION
Gastrointestinal stromal tumors (GISTs) are mesenchymal neo-
plasms that appear to be related to the interstitial cells of Cajal of 
the myenteric plexus [1, 2]. GISTs are characterized by high im-
munoreactivity to the thyrosine kinase receptor KIT (CD117) [3]. 
Approximately 80-95% of GISTs harbor mutations in the KIT gene 
[4, 5], and 5% have gain of function mutations in the platelet de-
rived growth factor receptor-alpha (PDGFR-α) gene [6]. Activat-
ing mutations in these genes trigger downstream signal pathways 
that cause increased cellular proliferation and decreased apopto-
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above the anal verge. The mass was hard, elastic, and immobile 
and had an irregular surface. Magnetic resonance imaging (MRI) 
revealed a lobulated tumor (measuring 9.0 × 6.3 cm) exhibiting 
intra- and extramural growth on the left lateral wall of the lower 
rectum, with compression displacement of the left levator muscle 
and prostatic gland, but there was no evidence of either pelvic 
lymphadenopathy or distant metastasis (Fig. 1A).
Transrectal ultrasound-guided biopsy samples showed the pres-
ence of a spindle cell tumor and immunohistochemical positivity 
for CD117 and CD34 (Fig. 1C, D), but was negative for α-SMA, 
S-100 protein. From the results of these examinations, a rectal GIST 
was diagnosed.
Because of the high grade, size and localization of the lesion, ima-
tinib mesylate (IM) neoadjuvant therapy was recommended. The 
patient, therefore, received IM therapy with a single daily dose of 
400 mg for 9 months and had follow-up within 3 months with CT 
scans to assess the therapeutic effect. During IM therapy, the tumor 
size continued to decrease (measuring 6.1 × 3.6 cm) and there were 
no side effects or evidence of progression. After 9 months of IM 
therapy, the CT and the MRI showed no remarkable size change, 
but a sharp demarcation had developed with respect to neighbor-
ing organs (Fig. 1B). He, therefore, underwent an ultralow ante-
rior resection with direct coloanal anastomosis and diverting ile-
ostomy. The ileostomy was closed 4 months after surgery.
The tumor, which measured 5 × 4 cm, was solid and had a well-
demarcated white tan on the cut sections (Fig. 1E). Histopathol-
ogy examination revealed that the tumor showed near total necro-
sis of tumor cells per 50 high power field (> 95%) (Fig. 1F). The 
resection margins were uninvolved on all sides, and there was no 
lymph node metastasis. The patient’s postoperative course has been 
satisfactory and there has been no recurrence for 6 months with-
out IM treatment.
Case 2
A 55-year-old man presented with a 12-month history of rectal 
pain and stool caliber change. A follow-up MRI showed a lobulated 
tumor (measuring 11.3 × 10.7 cm) arising from the anterior wall 
of the mid rectum, with upward displacement of the bilateral sem-
inal vesicle and compression of the prostate (Fig. 2A). Tumor abut-
ment was noted to the bladder base, prostate and proximal urethra. 
Abutment of the bilateral levator muscle without definite tumoral 
invasion was also noted, and several enlarged lymph nodes were 
found along the superior rectal vessel.
A transrectal ultrasound-guided biopsy showed a spindle cell stro-
mal tumor with focal coagulative necrosis, mild cytologic atypia, 
and immunohistochemical positivity for CD117, CD34 and S-100 
protein (Fig. 2C). The neoplastic cells were negative for α-SMA 
and desmin. The pathologic findings were consistent with a high-
grade GIST.
The patient began IM therapy at 400 mg once daily, and was fol-
A C B
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Fig. 1. Comparision of pre- and post-imatinib magnetic resonance imaging (MRI) and tumor tissue in case 1 undergoing neoadjuvant ima-
tinib therapy. (A) MRI before imatinib therapy revealed a 9 × 6.3 cm tumor with a necrotic portion involving the lower rectum. Compression 
displacement of the left levator muscle and prostatic gland can be seen. (B) MRI after 9 months of neoadjuvant imatinib therapy demonstrates 
a 6.1 × 3.6 cm residual tumor. (C) Biopsy specimen before neoadjuvant therapy showing spindle-cell tumor cells (H&E, × 200). (D) Immuno-
histochemical staining for c-kit was positive (c-Kit, × 200). (E) Gross specimen after neoadjuvant imatinib therapy demonstrating an ultralow 
anterior resection with a yellowish residual tumor mass. (F) Representative section of the tumor mass after imatinib therapy showing a hypo-
cellular myxohyaline stroma (H&E, × 400).Journal of The Korean Society of
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lowed-up within 3 months with CT scans. During IM therapy, the 
patient’s rectal pain decreased. Side effects included fatigue and 
skin eruption. After 9 months of IM therapy, the CT and the MRI 
showed no remarkable size change (measuring 8.2 × 4.5 cm) and 
no evidence of progression, but still compressive abutment to the 
prostate, seminal vesicle, and levator muscle (Fig. 2B). He under-
went an ultralow anterior resection with direct coloanal anastomo-
sis, diverting ileostomy and radical cystectomy with an ileal con-
duit. The ileostomy was closed 2 months after surgery.
The tumor, which measured 8 × 7 cm, was solid and had a yel-
low tan parenchyma with focal calcification on the cut sections 
(Fig. 2D). Histopathology examination revealed that the tumor 
showed extensive hyalinization and calcification (Fig. 2E). The tu-
mor cells were strongly positive for c-KIT (CD117) and CD34, 
and negative for α-SMA and S-100 protein (Fig. 2F). There were 
more than 10 mitoses per 50 high-power field. The patient’s post-
operative course has been satisfactory, and there has been no re-
currence for 12 months without IM treatment.
DISCUSSION
GISTs are the most common mesenchymal tumors of the gastro-
intestinal tract, with a worldwide incidence of approximately 15 per 
million [7]. GISTs occur throughout the GI tract, from the lower 
esophagus to the anus, but are found most commonly in the stom-
Table 1. Clinicopathological features of two cases
Case 1 Case 2
Sex/age Male/56 Male/55
Distance from AV (cm) 3.7 3
Size (cm) 9.0 × 6.3 11.3 × 10.7
CD 117 Positive Positive
CD 34 Positive Positive
Treatment duration (mo) 9 9
Side effects None Drug eruption
Residual size (cm) 6.1 × 3.6 8.2 × 4.5
Opeartion uLAR, CAA,  
diverting ileostomy
uLAR, CAA,  
diverting ileostomy,  
radical cystectomy, ICUD 
Mitosis
a Rare >10/50 HPFs
Follow-up
Time (mo) 6 12
Recurrence (mo) No No
uLAR, ultra-low anterior resection; CAA, coloanal anastomosis; ICUD, ileal conduit 
urinary diversion; HPF, high power field.
aHistopathological examination of case 1 revealed that the tumor showed near to-
tal necrosis of tumor cells per 50 high power field (>95%).
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Fig. 2. Comparision of pre- and post-imatinib magnetic resonance imaging (MRI) and tumor tissue in case 2 undergoing neoadjuvant ima-
tinib therapy. (A) MRI before imatinib therapy revealed a 11.3 × 10.7 cm, lobulated tumor arising from the anterior mesorectum of the low 
rectum. Abutment to the bladder base, the prostate and the bilateral levator muscle can be seen. (B) MRI after 9 months of neoadjuvant ima-
tinib therapy shows a 9.5 × 9 cm residual tumor. (C) Biopsy specimen before neoadjuvant imatinib treatment showing a spindle-cell stromal 
tumor with focal coagulotive necrosis and mild cytologic atypia (H&E, × 200). (D) Gross specimen after neoadjuvant imatinib therapy dem-
onstrating a yellowish residual tumor with attached prostate and seminal vesicles. (E) Representative section of the tumor mass after imatinib 
therapy showing extensive hyalinization (H&E, × 40). (F) Microfocus of c-Kit positive tumor cells (c-Kit, × 200).Journal of The Korean Society of
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ach (60%), followed by the jejunum, ileum (30%), duodenum (5%), 
and colorectum (<5%) [3]. In Korea, only a few studies have been 
reported. In those studies, colorectal GISTs occurred predominantly 
in the rectum and tended to be classified as high risk, which was 
the most important risk factor for recurrence [12-14].
Diagnoses of GISTs in the rectum do not generally differ from 
those of other rectal tumors. Digital examination of the rectum, 
colonoscopy, and transrectal ultrasound are essential for diagno-
sis, together with a preoperative biopsy, which plays a key role in 
the diagnosis of GISTs. The preoperative biopsy provides informa-
tion on immunohistochemical features such as CD117, CD34, and 
mitotic count. Furthermore, CT or MRI scanning is needed to de-
termine the level of local invasion and to detect the presence of 
possible metastases. In 2007, the Korean GIST Study Group pub-
lished the first clinical practice guidelines for accurate diagnosis 
and effective treatment of GISTs in Korea, which was updated in 
2010 [15].
The management of GISTs has evolved rapidly since imatinib was 
introduced. The mainstay of treatment for primary GISTs has been 
surgical resection. Although surgery is the only known potentially 
curative treatment for primary or marginally resectable GISTs, 40-
90% of surgically treated patients experience disease recurrence 
[16]. According to the 2002 US National Institutes of Health con-
sensus criteria, the most relevant factors for risk stratification after 
resection of localized GISTs are tumor size and mitotic index [3]. 
More recently, evaluations of more than 1,600 patients by the Armed 
Forces Institute of Pathology led to an expansion in the prognos-
tic criteria of localized GIST to include the tumor site, reflecting 
the fact that gastric GISTs are less aggressive than intestinal GISTs 
of the same size [17]. 
IM has been the standard first-line pharmacologic treatment in 
patients with locally unresectable, recurrent, or metastatic GISTs. 
In pivotal trials involving patients with advanced GISTs, IM has 
demonstrated an overall response rate (complete response plus par-
tial response) in 68% of patients, a clinical benefit in 84% of pa-
tients, a median time to progression of 24 months, and a median 
overall survival of 57 months [18, 19]. Because of such impressive 
clinical outcomes with IM monotherapy in advanced GISTs, IM 
has created interest in a variety of potential multimodal approaches 
that combine surgery with systemic therapy.
Recently, the ACOSOG Z9001 adjuvant trial of imatinib for pri-
mary GISTs indicated that this drug primarily benefited patients 
with larger tumors, which was manifested by enhanced disease-
free survival [20]. Based on the results of this trial, imatinib was 
recently approved as adjuvant therapy for GISTs by the US Fed-
eral Drug Administration and by the European Medicines Agency. 
However, the ideal dose and duration of imatinib in this setting 
remain a question. Several ongoing studies are evaluating the effi-
cacy of adjuvant imatinib in patients with primary GISTs who are 
at high risk for postoperative relapse. The most recent management 
guidelines in the National Comprehensive Cancer Network and 
the European Society of Medical Oncology recommend adjuvant 
imatinib for at least 1 year following complete resection in patients 
with intermediate- to high-risk GISTs [21, 22].
Some patients with localized unresectable or metastatic GISTs 
may become candidates for surgery after response to imatinib treat-
ment or a period of disease stabilization. Successful surgical resec-
tion has been reported in cases of previously unresectable disease 
following 3-12 months of imatinib therapy [21, 23]. Generally, max-
imal tumor response with no further decrease in size is reached 
after 6-12 months, and surgery can then be performed safely in 
the majority of cases [23]. Andtbacka et al. [24] compared the out-
comes of preoperative IM therapy combined with surgery for lo-
cally advanced and metastatic GISTs among 46 patients, including 
11 with locally advanced primary tumors and 35 with metastatic 
tumors. Complete surgical resection after IM neoadjuvant therapy 
was accomplished in all of the locally advanced primary tumors, 
but in only 31.4% (11/35) of the metastatic tumors. Based on these 
results, IM neoadjuvant therapy combined with surgery can be 
considered to be more effective for patients with primary GISTs. 
Neoadjuvant therapy with imatinib is being investigated for its ef-
fect on surgical outcomes.
Although treatment with imatinib results in a clinical response 
in the majority of advanced GIST patients, some patients are ini-
tially resistant or develop resistance to imatinib due to secondary 
mutations. Primary resistance to imatinib (progression within the 
first 6 months of therapy) is uncommon, but occurs in approxi-
mately 10% of patients, mostly those with mutations in KIT exon 
9 or PDGFR-α exon 18. Primary resistance is infrequently associ-
ated with secondary mutations. Approximately 67% of GIST pa-
tients develop secondary resistance to imatinib (progression after 
a minimum of 6 months of partial remission or SD) due to the 
appearance of secondary mutations, mainly in KIT exon 11 [25]. 
Determining the correct dosage of imatinib, the optimal duration 
of treatment and the best time of surgical intervention is, there-
fore, critical.
In our two cases, the patients responded to treatment with imatinib, 
as shown by CT or MRI for response assessment. After 9 months 
of IM neoadjuvant therapy, surgeons with multidisciplinary ex-
pertise, medical oncologists, radiologists, and gastroenterologists 
agreed that maximal benefit from imatinib had been achieved. We 
stopped the treatment and chose the surgical procedure before re-
sistance to imatinib or tumor progression could occur. The post-
operative courses of both patients have been satisfactory, and there 
have been no recurrences during the 6- and 12-month subsequent 
periods without IM treatment (Table 1).
The role of IM neoadjuvant therapy has been discussed and ex-
plored in many clinical trials [23, 26-29], but the optimal duration 
of therapy has not yet been determined. Based on our prior expe-
rience and the findings from our two cases, we believe that clinical 
decision making for locally advanced rectal GISTs requires multi-
disciplinary expertise and that choosing the ideal time for surgery 
after neoadjuvant therapy is critical. Further study should define 
the role of neoadjuvant imatinib in GISTs to optimize treatment Journal of The Korean Society of
Coloproctology
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outcomes. A multidisciplinary team approach should be empha-
sized. In addition, large clinical trials are required to determine the 
optimal duration of therapy and the optimal timing of surgery.
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